Newly approved cancer drug targets aggressive form of ‘deadly disease’
Newly approved cancer drug targets aggressive form of ‘deadly disease’A new drug regimen for certain types of pancreatic cancer recently received approval from the U.S. Food and Drug Administration (FDA) — the first new medication in nearly a decade.Onivyde (irinotecan liposome), an injectable medication made by Ipsen, has been approved for use along with oxaliplatin, fluorouracil and leucovorin as a regimen for patients with metastatic pancreatic adenocarcinoma (mPDAC).This type of cancer is an aggressive malignancy with an average life expectancy of between eight and 11 months, according to the National Institutes of Health (NIH).ON THIS DAY IN HISTORY, MARCH 6, 2019, ALEX TREBEK SHARES CANCER DIAGNOSIS WITH THE WORLDThe approval was based on a randomized, controlled trial that included 770 patients with metastatic pancreatic adenocarcinoma who had not previously received chemotherapy, according to an FDA press release.The group of patients who received the new regimen via IV infusion showed “significant…